Samuel Parisi - Alkermes Plc Interim Finance
| ALKS Stock | USD 34.60 0.68 2.00% |
Executive
Samuel Parisi is Interim Finance of Alkermes Plc
| Age | 50 |
| Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Web | https://www.alkermes.com |
Samuel Parisi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Samuel Parisi against Alkermes Plc stock is an integral part of due diligence when investing in Alkermes Plc. Samuel Parisi insider activity provides valuable insight into whether Alkermes Plc is net buyers or sellers over its current business cycle. Note, Alkermes Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alkermes Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Samuel Parisi over three weeks ago Disposition of 1327 shares by Samuel Parisi of Alkermes Plc at 35.69 subject to Rule 16b-3 | ||
Samuel Parisi over a year ago Disposition of 2559 shares by Samuel Parisi of Alkermes Plc at 29.65 subject to Rule 16b-3 |
Alkermes Plc Management Efficiency
The company has return on total asset (ROA) of 0.1254 % which means that it generated a profit of $0.1254 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.279 %, meaning that it created $0.279 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.20 in 2025. Return On Capital Employed is likely to gain to 0.28 in 2025. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 17.3 M in 2025, whereas Other Current Assets are likely to drop slightly above 53.5 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jessica Novak | Evolus Inc | N/A | |
| Esq III | Pacira BioSciences, | 50 | |
| Sauri Gudlavalleti | Dr Reddys Laboratories | 42 | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Charles Laranjeira | Pacira BioSciences, | 58 | |
| Thomas Rowland | ANI Pharmaceuticals | 58 | |
| Tammi Gaskins | Ironwood Pharmaceuticals | N/A | |
| Dong Yu | Dynavax Technologies | N/A | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| MBA MPH | Amphastar P | N/A | |
| Dennis McLoughlin | Pacira BioSciences, | 58 | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| David Boyer | Neurocrine Biosciences | 46 | |
| Christopher Mutz | ANI Pharmaceuticals | 54 | |
| Kristen JD | Pacira BioSciences, | 51 | |
| Ronald Silver | Ironwood Pharmaceuticals | 42 | |
| Richard Kahr | Pacira BioSciences, | N/A | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Juan MD | Intracellular Th | 54 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
Management Performance
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.13 |
Alkermes Plc Leadership Team
Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Norman, Senior Relations | ||
| David Gaffin, Senior Vice President Chief Legal Officer | ||
| Richard Pops, Chairman and CEO | ||
| Iain Brown, Chief Accounting Officer | ||
| Blair Jackson, Executive Officer | ||
| Declan OConnor, Health Environment | ||
| Samuel Parisi, Interim Finance | ||
| Stephen Schiavo, Senior Resources | ||
| Michael Landine, Senior Vice President - Corporate Development | ||
| Thomas Harvey, Chief IT | ||
| Craig MD, Executive Officer | ||
| Floyd MD, Founder | ||
| David JD, Chief VP | ||
| Sandra Coombs, Senior Relations |
Alkermes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 4.91 B | ||||
| Shares Outstanding | 162.61 M | ||||
| Shares Owned By Insiders | 1.44 % | ||||
| Shares Owned By Institutions | 98.56 % | ||||
| Number Of Shares Shorted | 11.57 M | ||||
| Price To Earning | (38.45) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.